Table 2.
Patient characteristics for phase I and phase II trials
| Characteristics | Phase I | Phase II |
| Total no. of evaluable patients | 39 | 56 |
| Males | 29 (74%) | 46 (82%) |
| Females | 10 (26%) | 10 (18%) |
| Age | ||
| Median (range) | 55 (23–75) | 59 (29–79) |
| Race | ||
| White | 38 (97%) | 47 (91%) |
| Black | 0 | 4 (7%) |
| Asian | 1 (3%) | 0 |
| Baseline ECOG performance status | ||
| 0 | 19 (42%) | 22 (39%) |
| 1 | 25 (56%) | 34 (61%) |
| 2 | 1 (2%) | 0 |
| Disease status | ||
| Measurable | 34 (87%) | All |
| Evaluable | 5 (13%) | |
| Location of primary malignancy | ||
| Esophagus | 10 (26%) | 21 (37%) |
| Gastroesophageal junction | 4 (10%) | 10 (18%) |
| Stomach | 13 (33%) | 25 (45%) |
| Unknown primary | 6 (15%) | 0 |
| Pancreas | 2 (5%) | 0 |
| Other (gastrinoma, islet cell carcinoma, breast small cell carcinoma, mesothelioma) | 4 (10%) | 0 |
| Histology | ||
| Adenocarcinoma | N/A | 55 (98%) |
| Squamous cell carcinoma | N/A | 1 (2%) |
| Location of metastases | ||
| Lung | 6 (15%) | 12 (20%) |
| Liver | 18 (46%) | 29 (49%) |
| Lymph nodes | 23 (59%) | 41 (69%) |
| Bone | 2 (3%) | 3 (5%) |
| Other | 19 (49%) | 15 (25%) |
ECOG, Eastern Cooperative Oncology Group.